Opinion|Videos|October 15, 2024
Exploring Oral Systemic Therapies For Plaque Psoriasis: Efficacy, Safety, and Clinical Considerations
Lauren Miller, MPAS, PA-C; Jayme M. Heim, MSN FNP-BC, and Kirk Gautier, PA-C, discuss recent advancements in plaque psoriasis treatment, focusing on novel oral systemic therapies like the TYK-2 inhibitor deucravacitinib and its clinical trial data, to inform therapeutic decisions for this systemic disease.
Advertisement
Advertisement
Related to this article
Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
From a CRISPR therapy's FDA priority review to oral HAE prophylaxis data and a needle-free epinephrine resubmission, 4 allergy stories from September.
As drinking declines, Stevan Gonzalez, MD, Frances Lee, MD, and Brian Lee, MD, on the lingering burden of alcohol-associated liver disease.
Check out highlights from news published on Day 2 of the EADV Congress 2026, spanning vitiligo, HS, atopic dermatitis, and more.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
Facial and total body repigmentation with upadacitinib kept rising through Week 76 in Viti-Up, with higher responses when NB-UVB was added.
DBV has requested priority review for the epicutaneous patch, supported by phase 3 VITESSE data showing a 31.8-point responder rate gain vs placebo.
Tilrekimig, a trispecific IL-4/IL-13/TSLP antibody, met its EASI-75 primary endpoint at all doses in a phase 2 atopic dermatitis trial.
Advertisement
Advertisement
Trending on HCPLive
1
US Alcohol Use Falls, but Not for Adults Aged 50 to 64, With Brian Lee, MD
2
Nail Detachment 4 Times More Common With GLP-1 Use
3
EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes
4
FDA Approves Mavacamten for Pediatric Patients With Obstructive HCM
5